Effects a Honey Based Syrup on Blood Parameters in Patients With Breast Cancer
Primary Purpose
Breast Cancer
Status
Completed
Phase
Phase 2
Locations
Iran, Islamic Republic of
Study Type
Interventional
Intervention
honey based (HB) syrup
Sponsored by

About this trial
This is an interventional supportive care trial for Breast Cancer focused on measuring breast cancer, honey, blood
Eligibility Criteria
Inclusion Criteria:
- Female gender
- Age between 18- 70 years old Patients
- known case of breast cancer
- Hemoglobin level is at least 8 g / dl
- Hematocrit level at least 30% The level of
- TSH is normal
Exclusion Criteria:
- Patients known case of heart disease with unstable conditions
- Disabling Pulmonary Disease and History of Asthma
- Patients known case of severe kidney disease (Creatinine level is greater than 2mg / dl Proteinuria)
- The SGOT level is more than 3 times of the normal threshold
- Bilirubin levels is greater than 2mg / dl
- Positive history of hypersensitivity to saffron, Rose water and Honey
- Uncontrolled pain
- severe infection
- serious illness
- Positive history of gout or high level of uric acid
- An individual who uses antidepressants due to depression
- Simultaneous use of drugs that affect blood cells
- Unwillingness to participate in the study
- Active treatment for anemia (transfusion or Epoetin Alfa Injection)
Sites / Locations
- Shohaday-e- Tajrish Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Intervention
Placebo
Arm Description
Group A: patients receiving HB syrup, 10 cc three times daily
Group B: patients receiving placebo, 10 cc three times daily
Outcomes
Primary Outcome Measures
The change of mean score of Hemoglobin level of patients in intervention and placebo groups
A mean score of hemoglobin level is generally defined as 12.5 to 14.5 grams per deciliter (125-145 grams per liter) for women. Higher or lower scores mean a worse outcome.
The change of mean score of WBC count of patients in intervention and placebo groups
A mean score of WBC count is usually between 4,000 and 11,000 per microliter of blood for women. Higher or lower scores mean a worse outcome.
The change of mean score of Plt count of patients in intervention and placebo groups
A mean score of Plt count is usually ranges from 150,000 to 450,000 platelets per microliter of blood for women. Higher or lower scores mean a worse outcome.
Secondary Outcome Measures
Full Information
NCT ID
NCT04426435
First Posted
June 7, 2020
Last Updated
October 6, 2020
Sponsor
Shiraz University of Medical Sciences
Collaborators
Shahid Beheshti University of Medical Sciences
1. Study Identification
Unique Protocol Identification Number
NCT04426435
Brief Title
Effects a Honey Based Syrup on Blood Parameters in Patients With Breast Cancer
Official Title
Honey Based Syrup on Blood Parameters
Study Type
Interventional
2. Study Status
Record Verification Date
October 2020
Overall Recruitment Status
Completed
Study Start Date
June 15, 2020 (Actual)
Primary Completion Date
September 25, 2020 (Actual)
Study Completion Date
October 5, 2020 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Shiraz University of Medical Sciences
Collaborators
Shahid Beheshti University of Medical Sciences
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Study aim Determination of the effect of a honey based (HB) syrup on the blood parameters of patients with breast cancer Design Two arm parallel group randomised clinical trial, double blinded Settings and conduct Design of the study: Women patients with breast cancer referring to Shohaday-e- Tajrish Hospital of Tehran who are under chemotherapy treatment. In order to blind the investigator, medications are named as "A" for syrup of HB and B for placebo. The patients don't aware of the type of drug they are assigned to. In addition, the groups are entered into statistical analysis as "A" and "B.
The patients will revive either A or B syrup for 4 weeks. At the beginning of the trial demographic data would be gathered. Also, a blood sample would be drawn at the beginning time and after the end of intervention period (week 4).
Data would be analysed by SPSS software using T-test.
Detailed Description
Women patients with breast cancer referring to Shohaday-e- Tajrish Hospital of Tehran who are under chemotherapy treatment. In order to blind the investigator, medications are named as "A" for syrup of HB and B for placebo. The patients don't aware of the type of drug they are assigned to. In addition, the groups are entered into statistical analysis as "A" and "B.
The patients will revive either A or B syrup for 4 weeks. At the beginning of the trial demographic data would be gathered. Also, a blood sample would be drawn at the beginning time and after the end of intervention period (week 4).
Data would be analysed by SPSS software using T-test. Main outcome variables The mean of score of "Hemoglobine (Hb)", 2. The mean of score of "white blood cell count (WBC)", 3. The mean of score of "platelet count (Plt)"
Main outcome variables The mean of score of "Hemoglobine (Hb)", 2. The mean of score of "white blood cell count (WBC)", 3. The mean of score of "platelet count (Plt)"
Participants/Inclusion and exclusion criteria Inclusion criteria: women suffer from breast cancer who are; 1.Age between 18- 70 years old; 2. Hemoglobin level is at least 8g/dl; 3. Hematocrit level at least 30%; 4. normal TSH. Exclusion criteria: 1. Heart disease with unstable conditions; 2. Disabling Pulmonary Disease and History of Asthma; 3. Severe kidney disease; 4. Creatinine level greater than 2mg/dl; 5. Proteinuria; 6. The SGOT level more than 3 times of the normal threshold; 7. Bilirubin levels greater than 2mg/dl; 8. Positive history of hypersensitivity to saffron, rose water and honey; 9. severe infection; 10. Systemic disease;11. Positive history of gout or high level of uric acid; 12. An individual who uses antidepressants due to depression; 13. Simultaneous use of drugs that affect fatigue; 14. Uncontrolled pain; 15. Unwillingness to participate in the study.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Breast Cancer
Keywords
breast cancer, honey, blood
7. Study Design
Primary Purpose
Supportive Care
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
60 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Intervention
Arm Type
Experimental
Arm Description
Group A: patients receiving HB syrup, 10 cc three times daily
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Group B: patients receiving placebo, 10 cc three times daily
Intervention Type
Drug
Intervention Name(s)
honey based (HB) syrup
Intervention Description
honey-based syrup is prepared according to the documented Persian Medicine manuscripts with some modifications. HB is a mixture of honey, rose water and saffron. Each 100g of HB consisted of 79.87 g honey, 19.97 g rose water, and 0.16 g saffron.
All the ingredients were licensed and approved by The Islamic Republic of Iran Food and Drug Organization (I.R.I.FDO).
Primary Outcome Measure Information:
Title
The change of mean score of Hemoglobin level of patients in intervention and placebo groups
Description
A mean score of hemoglobin level is generally defined as 12.5 to 14.5 grams per deciliter (125-145 grams per liter) for women. Higher or lower scores mean a worse outcome.
Time Frame
The weeks of 0 and 4 after treatment
Title
The change of mean score of WBC count of patients in intervention and placebo groups
Description
A mean score of WBC count is usually between 4,000 and 11,000 per microliter of blood for women. Higher or lower scores mean a worse outcome.
Time Frame
The weeks of 0 and 4 after treatment
Title
The change of mean score of Plt count of patients in intervention and placebo groups
Description
A mean score of Plt count is usually ranges from 150,000 to 450,000 platelets per microliter of blood for women. Higher or lower scores mean a worse outcome.
Time Frame
The weeks of 0 and 4 after treatment
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Female gender
Age between 18- 70 years old Patients
known case of breast cancer
Hemoglobin level is at least 8 g / dl
Hematocrit level at least 30% The level of
TSH is normal
Exclusion Criteria:
Patients known case of heart disease with unstable conditions
Disabling Pulmonary Disease and History of Asthma
Patients known case of severe kidney disease (Creatinine level is greater than 2mg / dl Proteinuria)
The SGOT level is more than 3 times of the normal threshold
Bilirubin levels is greater than 2mg / dl
Positive history of hypersensitivity to saffron, Rose water and Honey
Uncontrolled pain
severe infection
serious illness
Positive history of gout or high level of uric acid
An individual who uses antidepressants due to depression
Simultaneous use of drugs that affect blood cells
Unwillingness to participate in the study
Active treatment for anemia (transfusion or Epoetin Alfa Injection)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mehdi Pasalar
Organizational Affiliation
Shiraz University of Medical Sciences
Official's Role
Principal Investigator
Facility Information:
Facility Name
Shohaday-e- Tajrish Hospital
City
Tehran
Country
Iran, Islamic Republic of
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
25777290
Citation
Pasalar M, Choopani R, Mosaddegh M, Kamalinejad M, Mohagheghzadeh A, Fattahi MR, Ghanizadeh A, Bagheri Lankarani K. Efficacy and safety of jollab to treat functional dyspepsia: a randomized placebo-controlled clinical trial. Explore (NY). 2015 May-Jun;11(3):199-207. doi: 10.1016/j.explore.2015.02.007. Epub 2015 Feb 17.
Results Reference
result
PubMed Identifier
25587004
Citation
Pasalar M, Choopani R, Mosaddegh M, Kamalinejad M, Mohagheghzadeh A, Fattahi MR, Zarshenas MM, Jafari P, Lankarani KB. Efficacy of jollab in the treatment of depression in dyspeptic patients: a randomized double-blind controlled trial. J Evid Based Complementary Altern Med. 2015 Apr;20(2):104-8. doi: 10.1177/2156587214563542. Epub 2015 Jan 13.
Results Reference
result
PubMed Identifier
29743896
Citation
Emtiazy M, Oveidzadeh L, Habibi M, Molaeipour L, Talei D, Jafari Z, Parvin M, Kamalinejad M. Investigating the effectiveness of the Trigonella foenum-graecum L. (fenugreek) seeds in mild asthma: a randomized controlled trial. Allergy Asthma Clin Immunol. 2018 May 2;14:19. doi: 10.1186/s13223-018-0238-9. eCollection 2018.
Results Reference
result
PubMed Identifier
30858948
Citation
Taavoni S, Fathi L, Nazem-Ekbatani N, Haghani H. The Effect of Oral Intake of Honey Syrup on the Pain Intensity of Active Phase of Parturition of nulliparous women: A Randomized clinical trial. Caspian J Intern Med. 2019 Winter;10(1):98-101. doi: 10.22088/cjim.10.1.98.
Results Reference
result
Learn more about this trial
Effects a Honey Based Syrup on Blood Parameters in Patients With Breast Cancer
We'll reach out to this number within 24 hrs